News ArticleSai Life Sciences Reports 23% Revenue Growth in Q2 FY27 with ₹659 Crore Revenue Amid Strategic Expansion
Company advances integrated collaborations and invests ₹621 crore in capacity expansion during H1 FY27, sustaining EBITDA margin at 28%
Sai Life Sciences Limited reported a 23% year-on-year revenue increase to ₹659 crore in Q2 FY27, driven by growth in both CRO and CDMO segments. The company invested ₹621 crore in capex during H1 FY27 to expand capacity, and progressed strategic customer collaborations and pipeline molecules, supporting a stable EBITDA margin of 28% and robust operational momentum.
Sai Life Sciences Limited
Investor Presentation
Sai Life Sciences Limited announced a 23% year-over-year revenue growth to ₹659 crore for the second quarter of fiscal year 2027, supported by healthy performance in both its Contract Research (CRO) and Contract Development and Manufacturing Organization (CDMO) segments. The company reported an EBITDA margin of 28% and continued its capital expenditure with ₹621 crore invested in the first half of FY27 to expand capacity and capabilities.
The consolidated revenue for the half year ended September 30, 2026, rose to ₹1,213 crore, marking a 17% increase year-on-year, with material margin up by 19% to ₹893 crore. EBITDA for H1 FY27 reached ₹335 crore, showing a 19% year-on-year increase, and PAT was ₹172 crore, also up 19%.
The CDMO segment accounted for 64% of the revenue mix in Q2 FY27, with CRO contributing 36%. The company is on track to meet its overall capex projection of ₹1,100 to ₹1,300 crore for FY27, having already committed ₹358 crore in Q2 alone.
Sai Life Sciences progressed strategic collaborations, including commencing operations of its first end-to-end integrated outsourcing model and converting a large pharma relationship into a strategic engagement. The company also advanced molecules in its late-phase pipeline and maintained certifications for sustainable waste management and workplace quality.
The presentation reinforces Sai Life Sciences’ position as an integrated CRDMO partnering with over 300 global clients, including 19 of the top 25 pharmaceutical companies, and highlights the ongoing expansion of its manufacturing and R&D footprint across India, the UK, and the US.
Highlights
- Q2 FY27 revenue at ₹659 crore, a 23% increase year-on-year
- H1 FY27 revenue reaches ₹1,213 crore, growing 17% year-on-year
- EBITDA margin sustained at 28% in Q2 FY27
- Capex investment totals ₹621 crore in H1 FY27, focused on capacity expansion
- CDMO segment represents 64% of revenue mix in Q2 FY27
- First end-to-end integrated collaboration commenced operations, expected full functionality in Q3 FY27
Key Data Snapshot
What happened
- Sai Life Sciences posted a 23% year-over-year revenue increase to ₹659 crore in Q2 FY27.
- The EBITDA margin for Q2 FY27 stood at 28%, reflecting sustained operational efficiency.
- The company invested ₹621 crore in capital expenditures during the first half of FY27 to expand capacity and capabilities.
Key details
- CDMO segment accounted for 64% of Q2 FY27 revenue, while CRO contributed 36%.
- Revenue for H1 FY27 reached ₹1,213 crore, up 17% compared to H1 FY26.
- Capex for Q2 FY27 was ₹358 crore, supporting ongoing expansion projects.
- First end-to-end integrated outsourcing collaboration commenced operations, expected to be fully functional in Q3 FY27.
- Another large pharma relationship shifted to a strategic, integrated engagement model.
Business impact
- The company added a molecule to the late-phase pipeline and advanced one molecule to commercial stage, highlighting pipeline progression.
- Certification achievements include Zero Waste to Landfill Platinum for two units and Great Place To Work® certification for 2026–27.
- These operational improvements align with strategic priorities to support larger, multistage collaborations with pharmaceutical clients over the long term.
Background and context
- Founded in 1999, Sai Life Sciences is an integrated CRDMO offering services from drug discovery to commercial manufacturing.
- It serves over 300 global clients, including 19 of the top 25 pharmaceutical companies worldwide.
- The company has consistently grown, achieving a 26% CAGR in revenue over the past five years, with a strong focus on innovation and capacity expansion.
Highlights
- Q2 FY27 revenue at ₹659 crore, a 23% increase year-on-year
- H1 FY27 revenue reaches ₹1,213 crore, growing 17% year-on-year
- EBITDA margin sustained at 28% in Q2 FY27
- Capex investment totals ₹621 crore in H1 FY27, focused on capacity expansion
- CDMO segment represents 64% of revenue mix in Q2 FY27
- First end-to-end integrated collaboration commenced operations, expected full functionality in Q3 FY27
Disclosures
- SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
Source Information
More News on Investor Presentation
View allLatest corporate announcements and market updates in Investor Presentation.
Rubicon Research Limited Reports Nearly 40% Revenue Growth and 68% Profit Increase in Q2 FY26-27
Rubicon Research Limited posted significant financial growth for the quarter ended September 30, 2026, with revenue increasing by 39.9% year-on-year to ₹5,764 million and profit after tax rising 67.9% to ₹904 million. This performance includes the consolidation impact of its recent Arinna acquisition and reflects strong operational cash flows and product approvals.
Read Full Story
Inventurus Knowledge Solutions Reports Q2 FY27 Investor Presentation Highlighting AI-Driven Growth and Platform Innovation
Inventurus Knowledge Solutions Limited disclosed its investor presentation for the quarter and half-year ended September 30, 2026, emphasizing advancements in its AI-powered healthcare enablement platform, strategic execution plans, and ongoing partnerships to drive growth and optimize margins.
Read Full Story
Sterlite Technologies to Attend 29th CITIC CLSA India Forum and Host Plant Visit for Analysts in November 2026
Sterlite Technologies Limited will participate in the 29th CITIC CLSA India Forum on November 17, 2026, and conduct a plant visit for analysts and institutional investors on November 19, 2026, both events organized by Credit Lyonnais Securities Asia.
Read Full Story
